KLP Kapitalforvaltning AS boosted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 27.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 884,546 shares of the company's stock after purchasing an additional 192,300 shares during the period. KLP Kapitalforvaltning AS's holdings in Kenvue were worth $21,211,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. LPL Financial LLC lifted its position in shares of Kenvue by 4.9% in the fourth quarter. LPL Financial LLC now owns 2,064,405 shares of the company's stock worth $44,075,000 after buying an additional 96,030 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after buying an additional 1,636,741 shares in the last quarter. Corebridge Financial Inc. lifted its position in shares of Kenvue by 4.2% in the fourth quarter. Corebridge Financial Inc. now owns 525,602 shares of the company's stock worth $11,222,000 after buying an additional 21,209 shares in the last quarter. Zions Bancorporation N.A. lifted its position in shares of Kenvue by 13.2% in the fourth quarter. Zions Bancorporation N.A. now owns 223,555 shares of the company's stock worth $4,773,000 after buying an additional 26,026 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. lifted its position in shares of Kenvue by 3.2% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 65,376 shares of the company's stock worth $1,396,000 after buying an additional 2,041 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Stock Performance
KVUE traded up $0.32 on Friday, reaching $22.82. The company had a trading volume of 5,167,529 shares, compared to its average volume of 17,183,436. The stock has a 50-day moving average price of $22.05 and a 200-day moving average price of $22.33. Kenvue Inc. has a 1 year low of $18.10 and a 1 year high of $25.17. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $43.77 billion, a PE ratio of 41.48, a P/E/G ratio of 3.76 and a beta of 0.83.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.28 earnings per share. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. Citigroup decreased their price objective on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Bank of America decreased their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Barclays cut their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday, July 15th. Finally, UBS Group cut their target price on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and an average price target of $24.71.
View Our Latest Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
